

AR

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
8 August 2002 (08.08.2002)

PCT

(10) International Publication Number  
WO 02/061128 A2(51) International Patent Classification<sup>7</sup>: C12Q 1/68

(21) International Application Number: PCT/US01/44519

(22) International Filing Date:  
29 November 2001 (29.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:


60/250,121	1 December 2000 (01.12.2000)	US
60/250,470	4 December 2000 (04.12.2000)	US
09/796,491	2 March 2001 (02.03.2001)	US
09/877,095	11 June 2001 (11.06.2001)	US
09/988,784	20 November 2001 (20.11.2001)	US

(71) Applicant: RESPONSE GENETICS, INC. [US/US];  
1640 Marengo Street, 6th Floor, Los Angeles, CA 90033  
(US).(72) Inventor: DANENBERG, Kathleen, D.; 3367 Rubio  
Crest Drive, Altadena, CA 91001 (US).(74) Agents: MELORO, Thomas et al.; Kenyon & Kenyon,  
1500 K Street, N.W., Suite 700, Washington, DC 20005  
(US).(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,  
ZA, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).

## Published:

— without international search report and to be republished  
upon receipt of that report

[Continued on next page]

(54) Title: METHOD OF DETERMINING A CHEMOTHERAPEUTIC REGIMEN BASED ON *ERCC1* EXPRESSION

(57) Abstract: The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing *ERCC1* expression levels in fixed or fixed and paraffin embedded tissues and determine a platinum-based chemotherapy by examination of the amount of *ERCC1* mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level. More specifically, the invention provides to oligonucleotide primer pair *ERCC1* and methods comprising their use for detecting levels of *ERCC1* mRNA.

WO 02/061128 A2

**WO 02/061128 A2**

---



*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## METHOD OF DETERMINING A CHEMOTHERAPEUTIC REGIMEN BASED ON *ERCCI* EXPRESSION

### FIELD OF THE INVENTION

5       The present invention relates to prognostic methods which are useful in  
medicine, particularly cancer chemotherapy. More particularly, the invention  
relates to assessment of tumor cell gene expression in a patient. The survival of  
patients treated with chemotherapeutic agents that target DNA, especially agents that  
damage DNA in the manner of platinating agents is assayed by examining the  
10   mRNA expressed from genes involved in DNA repair in humans.

### BACKGROUND OF THE INVENTION

Cancer arises when a normal cell undergoes neoplastic transformation and  
becomes a malignant cell. Transformed (malignant) cells escape normal physiologic  
controls specifying cell phenotype and restraining cell proliferation. Transformed  
15   cells in an individual's body thus proliferate, forming a tumor. When a tumor is  
found, the clinical objective is to destroy malignant cells selectively while mitigating  
any harm caused to normal cells in the individual undergoing treatment.

Chemotherapy is based on the use of drugs that are selectively toxic  
(cytotoxic) to cancer cells. Several general classes of chemotherapeutic drugs have  
20   been developed, including drugs that interfere with nucleic acid synthesis, protein  
synthesis, and other vital metabolic processes. These generally are referred to as  
antimetabolite drugs. Other classes of chemotherapeutic drugs inflict damage on  
cellular DNA. Drugs of these classes generally are referred to as genotoxic.

Susceptibility of an individual neoplasm to a desired chemotherapeutic drug or combination of drugs often, however, can be accurately assessed only after a trial period of treatment. The time invested in an unsuccessful trial period poses a significant risk in the clinical management of aggressive malignancies.

5           The repair of damage to cellular DNA is an important biological process carried out by a cell's enzymatic DNA repair machinery. Unrepaired lesions in a cell's genome can impede DNA replication, impair the replication fidelity of newly synthesized DNA and/or hinder the expression of genes needed for cell survival. Thus, genotoxic drugs generally are considered more toxic to actively dividing cells  
10   that engage in DNA synthesis than to quiescent, nondividing cells. Normal cells of many body tissues are quiescent and commit infrequently to re-enter the cell cycle and divide. Greater time between rounds of cell division generally is afforded for the repair of DNA damage in normal cells inflicted by chemotherapeutic genotoxins. As a result, some selectivity is achieved for the killing of cancer cells. Many treatment  
15   regimens reflect attempts to improve selectivity for cancer cells by coadministering chemotherapeutic drugs belonging to two or more of these general classes.

          Because effective chemotherapy in solid tumors usually requires a combination of agents, the identification and quantification of determinants of resistance or sensitivity to each single drug has become an important tool to design  
20   individual combination chemotherapy.

          Two widely used genotoxic anticancer drugs that have been shown to damage cellular DNA are cisplatin (DDP) and carboplatin. Cisplatin and/or carboplatin currently are used in the treatment of selected, diverse neoplasms of epithelial and mesenchymal origin, including carcinomas and sarcomas of the  
25   respiratory, gastrointestinal and reproductive tracts, of the central nervous system,

and of squamous origin in the head and neck. Cisplatin in combination with other agents is currently preferred for the management of testicular carcinoma, and in many instances produces a lasting remission. (Loehrer *et al.*, 1984, 100 Ann. Int. Med. 704). Cisplatin (DDP) disrupts DNA structure through formation of

5 intrastrand adducts. Resistance to platinum agents such as DDP has been attributed to enhanced tolerance to platinum adducts, decreased drug accumulation, or enhanced DNA repair. Although resistance to DDP is multifactoral, alterations in DNA repair mechanisms probably play a significant role. Excision repair of bulky DNA adducts, such as those formed by platinum agents, appears to be mediated by

10 genes involved in DNA damage recognition and excision. Cleaver *et al.*, Carcinogenesis 11:875-882 (1990); Hoeijmakers *et al.*, Cancer Cells 2:311-320 (1990); Shivji *et al.*, Cell 69:367-374 (1992). Indeed, cells carrying a genetic defect in one or more elements of the enzymatic DNA repair machinery are extremely sensitive to cisplatin. Fraval *et al.* (1978), 51 Mutat. Res. 121, Beck and Brubaker

15 (1973), 116 J. Bacteriol 1247.

The excision repair cross-complementing (*ERCCI*) gene is essential in the repair of DNA adducts. The human *ERCCI* gene has been cloned. Westerveld *et al.*, Nature (London) 310:425-428 (1984); Tanaka *et al.*, Nature 348:73-76 (1990). Several studies using mutant human and hamster cell lines that are defective in this

20 gene and studies in human tumor tissues indicate that the product encoded by *ERCCI* is involved in the excision repair of platinum-DNA adducts. Dabholkar *et al.*, J. Natl. Cancer Inst. 84:1512-1517 (1992); Dijt *et al.*, Cancer Res. 48:6058-6062 (1988); Hansson *et al.*, Nucleic Acids Res. 18: 35-40 (1990).

When transfected into DNA-repair deficient CHO cells, *ERCCI* confers

25 cellular resistance to cisplatin along with the ability to repair platinum-DNA

adducts. Hansson et al., *Nucleic Acids Res.* 18: 35-40 (1990). Currently accepted models of excision repair suggest that the damage recognition/excision step is rate-limiting to the excision repair process.

The relative levels of expression of excision repair genes such as *ERCC1* in  
5 malignant cells from cancer patients receiving platinum-based therapy has been examined. Dabholkar et al., *J. Natl. Cancer Inst.* 84:1512-1517 (1992). *ERCC1* overexpression in gastric cancer patients has been reported to have a negative impact on tumor response and ultimate survival when treated with the chemotherapeutic regimen of cisplatin (DDP)/fluorouracil (Metzger, et al., *J Clin Oncol* 16: 309,  
10 1998). Recent evidence indicates that gemcitabine (Gem) may modulate *ERCC1* nucleotide excision repair (NER) activity. Thus, intratumoral levels of *ERCC1* expression may be a major prognostic factor for determining whether or not DDP and GEM would be an effective therapeutic cancer patients.

Most pathological samples are routinely fixed and paraffin-embedded (FPE)  
15 to allow for histological analysis and subsequent archival storage. Thus, most biopsy tissue samples are not useful for analysis of gene expression because such studies require a high integrity of RNA so that an accurate measure of gene expression can be made. Currently, gene expression levels can be only qualitatively monitored in such fixed and embedded samples by using immunohistochemical  
20 staining to monitor protein expression levels.

Until now, quantitative gene expression studies including those of *ERCC1* expression have been limited to reverse transcriptase polymerase chain reaction (RT-PCR) amplification of RNA from fresh or frozen tissue. U.S. Patent No. 5,705,336 to Reed et al., discloses a method of quantifying *ERCC1* mRNA from  
25 ovarian tumor tissue and determining whether that tissue will be sensitive to

platinum-based chemotherapy. Reed et al., quantify *ERCC1* mRNA from frozen ovarian tumor biopsies.

The use of frozen tissue by health care professionals as described in Reed et al., poses substantial inconveniences. Rapid biopsy delivery to avoid tissue and subsequent mRNA degradation is the primary concern when planning any RNA-based quantitative genetic marker assay. The health care professional performing the biopsy, must hastily deliver the tissue sample to a facility equipped to perform an RNA extraction protocol immediately upon tissue sample receipt. If no such facility is available, the clinician must promptly freeze the sample in order to prevent mRNA degradation. In order for the diagnostic facility to perform a useful RNA extraction protocol prior to tissue and RNA degradation, the tissue sample must remain frozen until it reaches the diagnostic facility, however far away that may be. Maintenance of frozen tissue integrity during transport using specialized couriers equipped with liquid nitrogen and dry ice, comes only at a great expense.

Routine biopsies generally comprise a heterogeneous mix of stromal and tumorous tissue. Unlike with fresh or frozen tissue, FPE biopsy tissue samples are readily microdissected and separated into stromal and tumor tissue and therefore, offer advantage over the use of fresh or frozen tissue. However, isolation of RNA from fixed tissue, and especially fixed and paraffin embedded tissue, results in highly degraded RNA, which is generally not applicable to gene expression studies.

A number of techniques exist for the purification of RNA from biological samples, but none is reliable for isolation of RNA from FPE samples. For example, Chomczynski (U.S. Pat. No. 5,346,994) describes a method for purifying RNA from tissues based on a liquid phase separation using phenol and guanidine isothiocyanate. A biological sample is homogenized in an aqueous solution of

phenol and guanidine isothiocyanate and the homogenate thereafter mixed with chloroform. Following centrifugation, the homogenate separates into an organic phase, an interphase and an aqueous phase. Proteins are sequestered in the organic phase, DNA in the interphase, and RNA in the aqueous phase. RNA can be  
5 precipitated from the aqueous phase. Unfortunately, this method is not applicable to fixed and paraffin-embedded (FPE) tissue samples.

Other known techniques for isolating RNA typically utilize either guanidine salts or phenol extraction, as described for example in Sambrook, J. *et al.*, (1989) at pp. 7.3-7.24, and in Ausubel, F. M. *et al.*, (1994) at pp. 4.0.3-4.4.7. Again, none of  
10 the known methods provides reproducible quantitative results in the isolation of RNA from paraffin-embedded tissue samples.

Techniques for the isolation of RNA from paraffin-embedded tissues are thus particularly needed for the study of gene expression in tumor tissues, since expression levels of certain receptors or enzymes can be used to determine the  
15 likelihood of success of a particular treatment.

There is a need for a method of quantifying *ERCC1* mRNA from paraffinized tissue in order to provide an early prognosis for proposed genotoxic cancer therapies. As a result, there has been a concerted yet unsuccessful effort in the art to obtain a quantification of *ERCC1* expression in fixed and paraffinized  
20 (FPE) tissue. Accordingly, it is the object of the invention to provide a method for assessing *ERCC1* levels in tissues fixed and paraffin-embedded (FPE) and prognosticate the probable resistance of a patient's tumor to treatment with DNA damaging agents, creating the type of lesions in DNA that are created by DNA platinating agents, by examination of the amount of *ERCC1* mRNA in a patient's  
25 tumor cells and comparing it to a predetermined threshold expression level.



### SUMMARY OF THE INVENTION

In one aspect of the invention there is provided a method for assessing levels of expression of *ERCC1* mRNA obtained from fixed and paraffin-embedded (FPE) fixed and paraffin-embedded (FPE) tumor cells.

5 In another aspect of the invention there is provided a method of quantifying the amount of *ERCC1* mRNA expression relative to an internal control from a fixed and paraffin-embedded (FPE) tissue sample. This method includes isolation of total mRNA from said sample and determining the quantity of *ERCC1* mRNA relative to the quantity of an internal control gene's mRNA.

10 In an embodiment of this aspect of the invention, there are provided oligonucleotide primers having the sequence of ERCC1-504F (SEQ ID NO: 1) or ERCC1-574R (SEQ ID NO:2) and sequences substantially identical thereto. The invention also provides for oligonucleotide primers having a sequence that hybridizes to SEQ ID NO: 1 or SEQ ID NO:2 or their complements under stringent  
15 conditions.

In yet another aspect of the invention there is provided a method for determining a chemotherapeutic regimen for a patient, comprising isolating RNA from a fixed and paraffin-embedded (FPE) tumor sample; determining a gene expression level of *ERCC1* in the sample; comparing the *ERCC1* gene expression  
20 levels in the sample with a predetermined threshold level for the *ERCC1* gene; and determining a chemotherapeutic regimen based on results of the comparison of the *ERCC1* gene expression level with the predetermined threshold level.

The invention further relates to a method of normalizing the uncorrected gene expression (UGE) of *ERCC1* relative to an internal control gene in a tissue

sample analyzed using TaqMan® technology to known *ERCC1* expression levels relative to an internal control from samples analyzed by pre-TaqMan® technology.

### DESCRIPTION OF THE DRAWING

Figure 1 is a graph showing the overall survival of patients receiving

5 Cisplatin/Gem treatment vs. Corrected Relative *ERCC1* Expression in NSCLC.

Patient Corrected Relative *ERCC1* Expression levels lower than the threshold of  $6.7 \times 10^{-3}$  correlated with significantly better survival. While patient Corrected Relative *ERCC1* Expression levels higher than the threshold of  $6.7 \times 10^{-3}$  correlated with significantly worse survival. (P=0.009 Log rank test)

10 Figure 2 is a chart illustrating how to calculate Corrected Relative *ERCC1* expression relative to an internal control gene. The chart contains data obtained with two test samples, (unknowns 1 and 2), and illustrates how to determine the uncorrected gene expression data (UGE). The chart also illustrates how to normalize UGE generated by the TaqMan® instrument with known relative *ERCC1* values determined by pre-TaqMan® technology. This is accomplished by multiplying UGE to a correction factor  $K_{ERCC1}$ . The internal control gene in the figure is  $\beta$ -actin and the calibrator RNA is Human Liver Total RNA (Stratagene, Cat. #735017).

20 Figure 3 is a table showing the demographic details of the 56 patients in the study, tumor stage and cell types. The median number of treatment cycles received was 3 (range 1-6). Fourteen patients (25%) had previously received chemotherapy, mostly (9 patients) taxane therapy alone or in combination with DDP or carboplatin. Three of the 56 patients had received radiotherapy and 5 patients had under gone surgical resection of the primary tumor.

Figure 4 is a table showing patients with Corrected *ERCC1* expression levels below the threshold had a significantly longer median survival of 61.6 weeks (95% C.I. 42.4, 80.7 weeks) compared to 20.4 weeks (95% C.I. 6.9, 33.9 weeks) for patients with Corrected *ERCC1* levels above the threshold. Adjusted for tumor stage, the log rank statistic for the association between low or high *ERCC1* expression and overall survival was 3.97 and the P value was 0.046. The unadjusted log rank results are shown in this figure. Also shown are factors that were significantly associated with overall survival on univariable analysis using Kaplan Meier survival curves and the log rank test. These were the presence of pretreatment weight loss and the ECOG performance status. Patient age ( $P=0.18$ ), sex ( $P=0.87$ ), tumor stage ( $P=0.99$ ), tumor cell type ( $P=0.63$ ), and presence of pleural effusion ( $P=0.71$ ) were not significant prognostic factors for overall survival. Corrected Relative *ERCC1* Expression level, ECOG performance status, and weight loss remained significant prognostic factors for survival in the Cox proportional hazards regression model multivariable analysis. P values for a Cox regression model stratified on tumor stage were 0.038 for *ERCC1*, 0.017 for weight loss, and 0.02 for ECOG performance status (PS 0 versus 1 or 2).

### DETAILED DESCRIPTION OF THE INVENTION

The present invention resides in part in the finding that the amount of *ERCC1* mRNA in a tumor correlates with survival in patients treated with DNA platinating agents. Patients with tumors expressing high levels of *ERCC1* mRNA are considered likely to be resistant to platinum-based chemotherapy and this have lower levels of survivability. Conversely, those patients whose tumors expressing low amounts of *ERCC1* mRNA are likely to be sensitive to platinum-based chemotherapy and have greater levels of survivability. A patient's relative expression of tumor *ERCC1* mRNA is judged by comparing it to a predetermined threshold expression level.

The invention relates to a method of quantifying the amount of *ERCC1* mRNA expression in fixed and paraffin-embedded (FPE) tissue relative to gene expression of an internal control. The present inventors have developed oligonucleotide primers that allow accurate assessment of *ERCC1* expression in tissues that have been fixed and embedded. The invention oligonucleotide primers, ERCC1-504F (SEQ ID NO: 1), ERCC1-574R (SEQ ID NO: 2), or oligonucleotide primers substantially identical thereto, preferably are used together with RNA extracted from fixed and paraffin embedded (FPE) tumor samples. This measurement of *ERCC1* gene expression may then be used for prognosis of platinum-based chemotherapy.

This embodiment of the invention involves first, a method for reliable extraction of RNA from an FPE sample and second, determination of the content of *ERCC1* mRNA in the sample by using a pair of oligonucleotide primers, preferably oligonucleotide primer pair ERCC1-504F (SEQ ID NO: 1) and ERCC1-574R (SEQ

ID NO: 2), or oligonucleotides substantially identical thereto, for carrying out reverse transcriptase polymerase chain reaction. RNA is extracted from the FPE cells by any of the methods for mRNA isolation from such samples as described in US Patent Application No. 09/469,338, filed December 20, 1999, and is hereby  
5 incorporated by reference in its entirety.

The present method can be applied to any type of tissue from a patient. For examination of resistance of tumor tissue, it is preferable to examine the tumor tissue. In a preferred embodiment, a portion of normal tissue from the patient from which the tumor is obtained, is also examined. Patients whose normal tissues are  
10 expected to be resistant to platinum-based chemotherapeutic compounds, i.e., show a high level of *ERCC1* gene expression, but whose tumors are expected to be sensitive to such compounds, i.e., show a low level of *ERCC1* gene expression, may then be treated with higher amounts of the chemotherapeutic composition.

Patients showing a level of *ERCC1* gene expression below the threshold  
15 level, may be treated with higher amounts of the chemotherapeutic composition because they are expected to have greater survivability than patients with tumors expressing a level of *ERCC1* gene expression above the threshold level.

Alternatively, the clinician may determine that patients with tumors expressing a level of *ERCC1* gene expression above the threshold level may not derive any  
20 significant benefit from chemotherapy given their low expected survivability.

The methods of the present invention can be applied over a wide range of tumor types. This allows for the preparation of individual "tumor expression profiles" whereby expression levels of *ERCC1* are determined in individual patient samples and response to various chemotherapeutics is predicted. Preferably, the

methods of the invention are applied to solid tumors, most preferably Non-Small Cell Lung Cancer (NSCLC) tumors. For application of some embodiments of the invention to particular tumor types, it is preferable to confirm the relationship of *ERCC1* gene expression levels to survivability by compiling a dataset that enables correlation of a particular *ERCC1* expression and clinical resistance to platinum-based chemotherapy.

A "predetermined threshold level", as defined herein, is a corrected relative level of *ERCC1* tumor expression above which it has been found that tumors are likely to be resistant to a platinum-based chemotherapeutic regimen. Tumor expression levels below this threshold level are likely to be found in tumors sensitive to platinum-based chemotherapeutic regimen. The range of corrected relative expression of *ERCC1*, expressed as a ratio of *ERCC1* :  $\beta$ -actin, among tumors responding to a platinum-based chemotherapeutic regimen is less than about  $6.7 \times 10^{-3}$ . Tumors that do not respond to a platinum-based chemotherapeutic regimen have relative expression of *ERCC1* :  $\beta$ -actin ratio above about  $6.7 \times 10^{-3}$ . See Example 4.

A "predetermined threshold level" is further defined as tumor corrected relative *ERCC1* expression levels above which patients receiving a platinum-based chemotherapeutic regimen are likely to have low survivability. Tumor corrected relative *ERCC1* expression levels below this threshold level in patients receiving a platinum-based chemotherapeutic regimen correlate to high patient survivability. The threshold corrected relative *ERCC1* expression, expressed as a ratio of *ERCC1* :  $\beta$ -actin, is about  $6.7 \times 10^{-3}$ . Figure 1, see Example 4. However, the present invention is not limited to the use of  $\beta$ -actin as an internal control gene.

In performing the method of this embodiment of the present invention, tumor cells are preferably isolated from the patient. Solid or lymphoid tumors or portions thereof are surgically resected from the patient or obtained by routine biopsy. RNA isolated from frozen or fresh samples is extracted from the cells by any of the  
5 methods typical in the art, for example, Sambrook, Fischer and Maniatis, Molecular Cloning, a laboratory manual, (2nd ed.), Cold Spring Harbor Laboratory Press, New York, (1989). Preferably, care is taken to avoid degradation of the RNA during the extraction process.

However, tissue obtained from the patient after biopsy is often fixed, usually  
10 by formalin (formaldehyde) or gluteraldehyde, for example, or by alcohol immersion. Fixed biological samples are often dehydrated and embedded in paraffin or other solid supports known to those of skill in the art. Non-embedded, fixed tissue may also be used in the present methods. Such solid supports are envisioned to be removable with organic solvents for example, allowing for subsequent rehydration  
15 of preserved tissue.

RNA is extracted from the FPE cells by any of the methods as described in US Patent Application No. 09/469,338, filed December 20, 1999, which is hereby incorporated by reference in its entirety. Fixed and paraffin-embedded (FPE) tissue samples as described herein refers to storable or archival tissue samples. RNA may  
20 be isolated from an archival pathological sample or biopsy sample which is first deparaffinized. An exemplary deparaffinization method involves washing the paraffinized sample with an organic solvent, such as xylene, for example. Deparaffinized samples can be rehydrated with an aqueous solution of a lower alcohol. Suitable lower alcohols, for example include, methanol, ethanol, propanols,

and butanols. Deparaffinized samples may be rehydrated with successive washes with lower alcoholic solutions of decreasing concentration, for example.

Alternatively, the sample is simultaneously deparaffinized and rehydrated. RNA is then extracted from the sample.

5 For RNA extraction, the fixed or fixed and deparaffinized samples can be homogenized using mechanical, sonic or other means of homogenization. Rehydrated samples may be homogenized in a solution comprising a chaotropic agent, such as guanidinium thiocyanate (also sold as guanidinium isothiocyanate). Homogenized samples are heated to a temperature in the range of about 50 to about 10 100 °C in a chaotropic solution, which contains an effective amount of a chaotropic agent, such as a guanidinium compound. A preferred chaotropic agent is guanidinium thiocyanate.

An "effective concentration of chaotropic agent" is chosen such that at an RNA is purified from a paraffin-embedded sample in an amount of greater than 15 about 10-fold that isolated in the absence of a chaotropic agent. Chaotropic agents include: guanidinium compounds, urea, formamide, potassium iodide, potassium thiocyanate and similar compounds. The preferred chaotropic agent for the methods of the invention is a guanidinium compound, such as guanidinium isothiocyanate (also sold as guanidinium thiocyanate) and guanidinium hydrochloride. Many 20 anionic counterions are useful, and one of skill in the art can prepare many guanidinium salts with such appropriate anions. The effective concentration of guanidinium solution used in the invention generally has a concentration in the range of about 1 to about 5M with a preferred value of about 4M. If RNA is already in solution, the guanidinium solution may be of higher concentration such that the final



concentration achieved in the sample is in the range of about 1 to about 5M. The guanidinium solution also is preferably buffered to a pH of about 3 to about 6, more preferably about 4, with a suitable biochemical buffer such as Tris-Cl. The chaotropic solution may also contain reducing agents, such as dithiothreitol (DTT) and  $\beta$ -mercaptoethanol (BME). The chaotropic solution may also contain RNase inhibitors.

Homogenized samples may be heated to a temperature in the range of about 50 to about 100 °C in a chaotropic solution, which contains an effective amount of a chaotropic agent, such as a guanidinium compound. A preferred chaotropic agent is guanidinium thiocyanate.

RNA is then recovered from the solution by, for example, phenol chloroform extraction, ion exchange chromatography or size-exclusion chromatography. RNA may then be further purified using the techniques of extraction, electrophoresis, chromatography, precipitation or other suitable techniques.

The quantification of *ERCC1* mRNA from purified total mRNA from fresh, frozen or fixed is preferably carried out using reverse-transcriptase polymerase chain reaction (RT-PCR) methods common in the art, for example. Other methods of quantifying of *ERCC1* mRNA include for example, the use of molecular beacons and other labeled probes useful in multiplex PCR. Additionally, the present invention envisages the quantification of *ERCC1* mRNA via use of PCR-free systems employing, for example fluorescent labeled probes similar to those of the Invader® Assay (Third Wave Technologies, Inc.). Most preferably, quantification of *ERCC1* cDNA and an internal control or house keeping gene (e.g.  $\beta$ -actin) is done using a fluorescence based real-time detection method (ABI PRISM 7700 or 7900

Sequence Detection System [TaqMan®], Applied Biosystems, Foster City, CA.) or similar system as described by Heid *et al.*, (Genome Res 1996;6:986-994) and Gibson *et al.* (Genome Res 1996;6:995-1001). The output of the ABI 7700 (TaqMan® Instrument) is expressed in Ct's or "cycle thresholds". With the

5 TaqMan® system, a highly expressed gene having a higher number of target molecules in a sample generates a signal with fewer PCR cycles (lower Ct) than a gene of lower relative expression with fewer target molecules (higher Ct).

As used herein, a "house keeping" gene or "internal control" is meant to include any constitutively or globally expressed gene whose presence enables an

10 assessment of *ERCC1* mRNA levels. Such an assessment comprises a determination of the overall constitutive level of gene transcription and a control for variations in RNA recovery. "House-keeping" genes or "internal controls" can include, but are not limited to the cyclophilin gene,  $\beta$ -actin gene, the transferrin receptor gene, GAPDH gene, and the like. Most preferably, the internal control gene is  $\beta$ -actin

15 gene as described by Eads *et al.*, Cancer Research 1999; 59:2302-2306.

A control for variations in RNA recovery requires the use of "calibrator RNA." The "calibrator RNA" is intended to be any available source of accurately pre-quantified control RNA. Preferably, Human Liver Total RNA (Stratagene, Cat. #735017) is used.

20 "Uncorrected Gene Expression (UGE)" as used herein refers to the numeric output of *ERCC1* expression relative to an internal control gene generated by the TaqMan® instrument. The equation used to determine UGE is shown in Example 3, and illustrated with sample calculations in Figure 2.

A further aspect of this invention provides a method to normalize

uncorrected gene expression (UGE) values acquired from the TaqMan® instrument with "known relative gene expression" values derived from non-TaqMan® technology. Preferably, the known non-TaqMan® derived relative *ERCC1* :  $\beta$ -actin expression values are normalized with TaqMan® derived *ERCC1* UGE values  
5 from a tissue sample.

"Corrected Relative *ERCC1* Expression" as used herein refers to normalized *ERCC1* expression whereby UGE is multiplied with a *ERCC1* specific correction factor ( $K_{ERCC1}$ ), resulting in a value that can be compared to a known range of *ERCC1* expression levels relative to an internal control gene. Example 3 and Figure  
10 2 illustrate these calculations in detail. These numerical values allow the determination of whether or not the "Corrected Relative *ERCC1* Expression" of a particular sample falls above or below the "predetermined threshold" level. The predetermined threshold level of Corrected Relative *ERCC1* Expression to  $\beta$ -actin level is about  $6.7 \times 10^{-3}$ .  $K_{ERCC1}$  specific for *ERCC1*, the internal control  $\beta$ -actin and  
15 calibrator Human Liver Total RNA (Stratagene; Cat. #735017), is  $1.54 \times 10^{-3}$ .

"Known relative gene expression" values are derived from previously analyzed tissue samples and are based on the ratio of the RT-PCR signal of a target gene to a constitutively expressed internal control gene (e.g.  $\beta$ -Actin, GAPDH, etc.). Preferably such tissue samples are formalin fixed and paraffin-embedded (FPE)  
20 samples and RNA is extracted from them according to the protocol described in Example 1 and in US Patent Application No. 09/469,338, filed December 20, 1999, which is hereby incorporated by reference in its entirety. To quantify gene expression relative to an internal control standard quantitative RT-PCR technology known in the art is used. Pre-TaqMan® technology PCR reactions are run for a

fixed number of cycles (i.e., 30) and endpoint values are reported for each sample.

These values are then reported as a ratio of *ERCC1* expression to  $\beta$ -actin expression.

See U.S. Patent No. 5,705,336 to Reed et al.

$K_{ERCC1}$  may be determined for an internal control gene other than  $\beta$ -actin  
5 and/or a calibrator RNA different than Human Liver Total RNA (Stratagene, Cat.  
#735017). To do so, one must calibrate both the internal control gene and the  
calibrator RNA to tissue samples for which *ERCC1* expression levels relative to that  
particular internal control gene have already been determined (i.e., "known relative  
gene expression"). Preferably such tissue samples are formalin fixed and paraffin-  
10 embedded (FPE) samples and RNA is extracted from them according to the protocol  
described in Example 1 and in US Patent Application No. 09/469,338, filed  
December 20, 1999, which is hereby incorporated by reference in its entirety. Such  
a determination can be made using standard pre-TaqMan®, quantitative RT-PCR  
techniques well known in the art. Upon such a determination, such samples have  
15 "known relative gene expression" levels of *ERCC1* useful in the determining a new  
 $K_{ERCC1}$  specific for the new internal control and/or calibrator RNA as described in  
Example 3.

The methods of the invention are applicable to a wide range of tissue and  
tumor types and so can be used for assessment of clinical treatment of a patient and  
20 as a diagnostic or prognostic tool for a range of cancers including breast, head and  
neck, lung, esophageal, colorectal, and others. In a preferred embodiment, the  
present methods are applied to prognosis of Non-Small Cell Lung Cancer (NSCLC).

Pre-chemotherapy treatment tumor biopsies are usually available only as  
fixed paraffin embedded (FPE) tissues, generally containing only a very small

amount of heterogeneous tissue. Such FPE samples are readily amenable to microdissection, so that *ERCC1* gene expression may be determined in tumor tissue uncontaminated with stromal tissue. Additionally, comparisons can be made between stromal and tumor tissue within a biopsy tissue sample, since such samples  
5 often contain both types of tissues.

Generally, any oligonucleotide pair that flanks a region of *ERCC1* gene may be used to carry out the methods of the invention. Primers hybridizing under stringent conditions to a region of the *ERCC1* gene for use in the present invention will amplify a product between 20-1000 base pairs, preferably 50-100 base pairs,  
10 most preferably less than 100 base pairs.

The invention provides specific oligonucleotide primers pairs and oligonucleotide primers substantially identical thereto, that allow particularly accurate assessment of *ERCC1* expression in FPE tissues. Preferable are oligonucleotide primers, ERCC1-504F (SEQ ID NO: 1) and ERCC1 (SEQ ID NO:  
15 2), (also referred to herein as the oligonucleotide primer pair ERCC1) and oligonucleotide primers substantially identical thereto. The oligonucleotide primers ERCC1-504F (SEQ ID NO: 1) and ERCC1, (SEQ ID NO: 2) hybridize to the *ERCC1* gene (SEQ ID NO: 7) under stringent conditions and have been shown to be particularly effective for measuring *ERCC1* mRNA levels using RNA extracted  
20 from the FPE cells by any of the methods for mRNA isolation, for example as described Example 1 and in US Patent Application No. 09/469,338, filed December 20, 1999, which is hereby incorporated by reference in its entirety.

"Substantially identical" in the nucleic acid context as used herein, means hybridization to a target under stringent conditions, and also that the nucleic acid

segments, or their complementary strands, when compared, are the same when properly aligned, with the appropriate nucleotide insertions and deletions, in at least about 60% of the nucleotides, typically, at least about 70%, more typically, at least about 80%, usually, at least about 90%, and more usually, at least, about 95-98% of the nucleotides. Selective hybridization exists when the hybridization is more selective than total lack of specificity. See, Kanehisa, Nucleic Acids Res., 12:203-213 (1984).

This invention includes substantially identical oligonucleotides that hybridize under stringent conditions (as defined herein) to all or a portion of the oligonucleotide primer sequence of ERCC1-504F (SEQ ID NO: 1), its complement or ERCC1-574R (SEQ ID NO: 2), or its complement.

Under stringent hybridization conditions, only highly complementary, i.e., substantially similar nucleic acid sequences hybridize. Preferably, such conditions prevent hybridization of nucleic acids having 4 or more mismatches out of 20 contiguous nucleotides, more preferably 2 or more mismatches out of 20 contiguous nucleotides, most preferably one or more mismatch out of 20 contiguous nucleotides.

The hybridizing portion of the nucleic acids is typically at least 10 (e.g., 15) nucleotides in length. The hybridizing portion of the hybridizing nucleic acid is at least about 80%, preferably at least about 95%, or most preferably about at least 98%, identical to the sequence of a portion or all of oligonucleotide primer ERCC1-504F (SEQ ID NO: 1), its complement or ERCC1-574R (SEQ ID NO: 2), or its complement.

Hybridization of the oligonucleotide primer to a nucleic acid sample under

stringent conditions is defined below. Nucleic acid duplex or hybrid stability is expressed as a melting temperature ( $T_m$ ), which is the temperature at which the probe dissociates from the target DNA. This melting temperature is used to define the required stringency conditions. If sequences are to be identified that are

5 substantially identical to the probe, rather than identical, then it is useful to first establish the lowest temperature at which only homologous hybridization occurs with a particular concentration of salt (e.g. SSC or SSPE). Then assuming that 1% mismatching results in a  $1^\circ\text{C}$  decrease in  $T_m$ , the temperature of the final wash in the hybridization reaction is reduced accordingly (for example, if sequences having

10  $>95\%$  identity with the probe are sought, the final wash temperature is decrease by  $5^\circ\text{C}$ ). In practice, the change in  $T_m$  can be between  $0.5^\circ\text{C}$  and  $1.5^\circ\text{C}$  per 1% mismatch.

Stringent conditions involve hybridizing at  $68^\circ\text{C}$  in 5x SSC/5x Denhart's solution/1.0% SDS, and washing in 0.2x SSC/0.1% SDS at room temperature.

15 Moderately stringent conditions include washing in 3x SSC at  $42^\circ\text{C}$ . The parameters of salt concentration and temperature be varied to achieve optimal level of identity between the primer and the target nucleic acid. Additional guidance regarding such conditions is readily available in the art, for example, Sambrook, Fischer and Maniatis, Molecular Cloning, a laboratory manual, (2nd ed.), Cold

20 Spring Harbor Laboratory Press, New York, (1989) and F. M. Ausubel et al eds., Current Protocols in Molecular Biology, John Wiley and Sons (1994).

Oligonucleotide primers disclosed herein are capable of allowing accurate assessment of *ERCC1* gene expression in a fixed or fixed and paraffin embedded tissue, as well as frozen or fresh tissue. This is despite the fact that RNA derived

from FPE samples is more fragmented relative to that of fresh or frozen tissue.

Thus, the methods of the invention are suitable for use in assaying *ERCC1* expression levels in FPE tissue where previously there existed no way to assay *ERCC1* gene expression using fixed tissues.

5           From the measurement of the amount of *ERCC1* mRNA that is expressed in the tumor, the skilled practitioner can make a prognosis concerning clinical resistance of a tumor to a particular genotoxin or the survivability of a patient receiving a particular genotoxin. A platinum-based chemotherapy or a chemotherapy inducing a similar type of DNA damage, is the preferable genotoxin.

10           Platinum-based chemotherapies cause a "bulky adduct" of the DNA, wherein the primary effect is to distort the three-dimensional conformation of the double helix. Such compounds are meant to be administered alone, or together with other chemotherapies such as gemcitabine (Gem) or 5-Fluorouracil (5-FU).

          Platinum-based genotoxic chemotherapies comprises heavy metal  
15   coordination compounds which form covalent DNA adducts. Generally, these heavy metal compounds bind covalently to DNA to form, in pertinent part, cis-1,2-intrastrand dinucleotide adducts. Generally, this class is represented by cis-diamminedichloroplatinum (II) (cisplatin), and includes cis-diammine-(1,1-cyclobutanedicarboxylato) platinum(II) (carboplatin), cis-diammino -  
20   (1,2-cyclohexyl) dichloroplatinum(II), and cis-(1,2-ethylenediammine) dichloroplatinum(II). Platinum first agents include analogs or derivatives of any of the foregoing representative compounds.

          Tumors currently manageable by platinum coordination compounds include testicular, endometrial, cervical, gastric, squamous cell, adrenocortical and small cell



lung carcinomas along with medulloblastomas and neuroblastomas.

Trans-Diamminedichloroplatinum (II) (trans-DDP) is clinically useless owing, it is thought, to the rapid repair of its DNA adducts. The use of trans-DDP as a chemotherapeutic agent herein likely would provide a compound with low toxicity  
5 in nonselected cells, and high relative toxicity in selected cells. In a preferred embodiment, the platinum compound is cisplatin.

Many compounds are commonly given with platinum-based chemotherapy agents. For example, BEP (bleomycin, etoposide, cisplatin) is used for testicular cancer, MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) is used for bladder  
10 cancer, MVP (mitomycin C, vinblastine, cisplatin) is used for non-small cell lung cancer treatment. Many studies have documented interactions between platinum-containing agents. Therapeutic drug synergism, for example, has been reported for many drugs potentially included in a platinum based chemotherapy. A very short list of recent references for this include the following: Okamoto et al., Urology 2001;  
15 57:188-192.; Tanaka et al., Anticancer Research 2001; 21:313-315; Slamon et al., Seminars in Oncology 2001; 28:13-19; Lidor et al., Journal of Clinical Investigation 1993; 92:2440-2447; Leopold et al., NCI Monographs 1987;99-104; Ohta et al., Cancer Letters 2001; 162:39-48; van Moorsel et al., British Journal of Cancer 1999; 80:981-990.

20 Other genotoxic agents are those that form persistent genomic lesions and are preferred for use as chemotherapeutic agents in the clinical management of cancer. The rate of cellular repair of genotoxin-induced DNA damage, as well as the rate of cell growth via the cell division cycle, affects the outcome of genotoxin therapy. Unrepaired lesions in a cell's genome can impede DNA replication, impair the

replication fidelity of newly synthesized DNA or hinder the expression of genes needed for cell survival. Thus, one determinant of a genotoxic agent's cytotoxicity (propensity for contributing to cell death) is the resistance of genomic lesions formed therefrom to cellular repair. Genotoxic agents that form persistent genomic  
5 lesions, e.g., lesions that remain in the genome at least until the cell commits to the cell cycle, generally are more effective cytotoxins than agents that form transient, easily repaired genomic lesions.

A general class of genotoxic compounds that are used for treating many cancers and that are affected by levels of *ERCC1* expression are DNA alkylating  
10 agents and DNA intercalating agents. Psoralens are genotoxic compounds known to be useful in the photochemotherapeutic treatment of cutaneous diseases such as psoriasis, vitiligo, fungal infections and cutaneous T cell lymphoma. Harrison's Principles of Internal Medicine, Part 2 Cardinal Manifestations of Disease, Ch. 60 (12th ed. 1991). Another general class of genotoxic compounds, members of which  
15 can alkylate or intercalate into DNA, includes synthetically and naturally sourced antibiotics. Of particular interest herein are antineoplastic antibiotics, which include but are not limited to the following classes of compounds represented by: amsacrine; actinomycin A, C, D (alternatively known as dactinomycin) or F (alternatively KS4); azaserine; bleomycin; carminomycin (carubicin), daunomycin (daunorubicin), or  
20 14-hydroxydaunomycin (adriamycin or doxorubicin); mitomycin A, B or C; mitoxantrone; plicamycin (mithramycin); and the like.

Still another general class of genotoxic agents that are commonly used and that alkylate DNA, are those that include the haloethylnitrosoureas, especially the chloroethylnitrosoureas. Representative members of this broad class include

carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine and streptozotocin. Haloethylnitrosourea first agents can be analogs or derivatives of any of the foregoing representative compounds.

Yet another general class of genotoxic agents, members of which alkylate  
5 DNA, includes the sulfur and nitrogen mustards. These compounds damage DNA primarily by forming covalent adducts at the N7 atom of guanine. Representative members of this broad class include chlorambucil, cyclophosphamide, ifosfamide, melphalan, mechloroethamine, novembicin, trofosfamide and the like. Oligonucleotides or analogs thereof that interact covalently or noncovalently with  
10 specific sequences in the genome of selected cells can also be used as genotoxic agents, if it is desired to select one or more predefined genomic targets as the locus of a genomic lesion.

Another class of agents, members of which alkylate DNA, include the ethylenimines and methylmelamines. These classes include altretamine  
15 (hexamethylmelamine), triethylenephosphoramidate (TEPA), triethylenethiophosphoramidate (ThioTEPA) and triethylenemelamine, for example.

Additional classes of DNA alkylating agents include the alkyl sulfonates, represented by busulfan; the azinidines, represented by benzodepa; and others, represented by, e.g., mitoguazone, mitoxantrone and procarbazine. Each of these  
20 classes includes analogs and derivatives of the respective representative compounds.

The invention being thus described, practice of the invention is illustrated by the experimental examples provided below. The skilled practitioner will realize that the materials and methods used in the illustrative examples can be modified in

various ways. Such modifications are considered to fall within the scope of the present invention.

## EXAMPLES

### EXAMPLE 1

#### *RNA Isolation from FPE Tissue*

RNA is extracted from paraffin-embedded tissue by the following general  
5 procedure.

##### **A. Deparaffinization and hydration of sections:**

(1) A portion of an approximately 10  $\mu$ M section is placed in a 1.5 mL  
plastic centrifuge tube.

(2) 600  $\mu$ L of xylene are added and the mixture is shaken vigorously for  
10 about 10 minutes at room temperature (roughly 20 to 25 °C).

(3) The sample is centrifuged for about 7 minutes at room temperature at the  
maximum speed of the bench top centrifuge (about 10-20,000 x g).

(4) Steps 2 and 3 are repeated until the majority of paraffin has been  
dissolved. Two or more times are normally required depending on the amount of  
15 paraffin included in the original sample portion.

(5) The xylene solution is removed by vigorously shaking with a lower  
alcohol, preferably with 100% ethanol (about 600  $\mu$ L) for about 3 minutes.

(6) The tube is centrifuged for about 7 minutes as in step (3). The  
supernatant is decanted and discarded. The pellet becomes white.

(7) Steps 5 and 6 are repeated with successively more dilute ethanol  
20 solutions: first with about 95% ethanol, then with about 80% and finally with  
about 70% ethanol.

(8) The sample is centrifuged for 7 minutes at room temperature as in step  
(3). The supernatant is discarded and the pellet is allowed to dry at room

temperature for about 5 minutes.

#### **B. RNA Isolation with Phenol-Chloroform**

(1) 400  $\mu$ L guanidine isothiocyanate solution including 0.5% sarcosine and 8  $\mu$ L dithiothreitol is added.

5       (2) The sample is then homogenized with a tissue homogenizer (Ultra-Turrax, IKA-Works, Inc., Wilmington, NC) for about 2 to 3 minutes while gradually increasing the speed from low speed (speed 1) to high speed (speed 5).

(3) The sample is then heated at about 95 °C for about 5-20 minutes. It is preferable to pierce the cap of the tube containing the sample with a fine gauge  
10       needle before heating to 95 °C. Alternatively, the cap may be affixed with a plastic clamp or with laboratory film.

(4) The sample is then extracted with 50  $\mu$ L 2M sodium acetate at pH 4.0 and 600  $\mu$ L of phenol/chloroform/isoamyl alcohol (10:1.93:0.036), prepared fresh by mixing 18 mL phenol with 3.6 mL of a 1:49 isoamyl alcohol:chloroform solution.  
15       The solution is shaken vigorously for about 10 seconds then cooled on ice for about 15 minutes.

(5) The solution is centrifuged for about 7 minutes at maximum speed. The upper (aqueous) phase is transferred to a new tube.

(6) The RNA is precipitated with about 10  $\mu$ L glycogen and with 400  
20        $\mu$ L isopropanol for 30 minutes at -20 °C.

(7) The RNA is pelleted by centrifugation for about 7 minutes in a benchtop centrifuge at maximum speed; the supernatant is decanted and discarded; and the pellet washed with approximately 500  $\mu$ L of about 70 to 75% ethanol.

(8) The sample is centrifuged again for 7 minutes at maximum speed. The

supernatant is decanted and the pellet air dried. The pellet is then dissolved in an appropriate buffer for further experiments (e.g., 50  $\mu$ l. 5mM Tris chloride, pH 8.0).

## EXAMPLE 2

### *mRNA Reverse Transcription and PCR*

5        **Reverse Transcription:** RNA was isolated from microdissected or non-microdissected formalin fixed paraffin embedded (FPE) tissue as illustrated in Example 1 and as previously described in U.S. Application No. 09/469,338 filed December 20, 1999, which is hereby incorporated by reference in its entirety. After precipitation with ethanol and centrifugation, the RNA pellet was dissolved in 50  $\mu$ l  
10 of 5 mM Tris/Cl at pH 8.0. M-MLV Reverse Transcriptase will extend an oligonucleotide primer hybridized to a single-stranded RNA or DNA template in the presence of deoxynucleotides, producing a complementary strand. The resulting RNA was reverse transcribed with random hexamers and M-MLV Reverse Transcriptase from Life Technologies. The reverse transcription was accomplished  
15 by mixing 25  $\mu$ l of the RNA solution with 25.5  $\mu$ l of "reverse transcription mix" (see below). The reaction was placed in a thermocycler for 8 min at 26° C (for binding the random hexamers to RNA), 45 min at 42° C (for the M-MLV reverse transcription enzymatic reaction) and 5 min at 95° C (for heat inactivation of DNase).

20        "Reverse transcription mix" consists of 10  $\mu$ l 5X buffer (250 mM Tris-HCl, pH 8.3, 375 mM KCl, 15 mM MgCl<sub>2</sub>), 0.5  $\mu$ l random hexamers (50 O.D. dissolved in 550  $\mu$ l of 10 mM Tris-HCl pH 7.5) 5  $\mu$ l 10 mM dNTPs (dATP, dGTP, dCTP and dTTP), 5  $\mu$ l 0.1 M DTT, 1.25  $\mu$ l BSA (3mg/ml in 10 mM Tris-HCL, pH 7.5), 1.25  $\mu$ l

RNA Guard 24,800U/ml (RNase inhibitor) (Porcine #27-0816, Amersham Pharmacia) and 2.5 ul MMLV 200U/ul (Life Tech Cat #28025-02).

Final concentrations of reaction components are: 50 mM Tris-HCl, pH 8.3, 75 mM KCl, 3 mM MgCl<sub>2</sub>, 1.0 mM dNTP, 1.0 mM DTT, 0.00375 mg/ml BSA, 5 0.62 U/ul RNA Guard and 10 U/ul MMLV.

**PCR Quantification of mRNA expression.** Quantification of *ERCC1* cDNA and an internal control or house keeping gene (e.g.,  $\beta$ -actin) cDNA was done using a fluorescence based real-time detection method (ABI PRISM 7700 or 7900 Sequence Detection System [TaqMan®], Applied Biosystems, Foster City, CA.) as 10 described by Heid *et al.*, (Genome Res 1996;6:986-994); Gibson *et al.*, (Genome Res 1996;6:995-1001). In brief, this method uses a dual labelled fluorogenic TaqMan® oligonucleotide probe, (ERCC1-530Tc (SEQ ID NO: 3),  $T_m = 70^\circ \text{C}$ ), that anneals specifically within the forward and reverse primers. Laser stimulation within the capped wells containing the reaction mixture causes emission of a 3'quencher dye 15 (TAMRA) until the probe is cleaved by the 5' to 3' nuclease activity of the DNA polymerase during PCR extension, causing release of a 5' reporter dye (6FAM). Production of an amplicon thus causes emission of a fluorescent signal that is detected by the TaqMan®'s CCD (charge-coupled device) detection camera, and the amount of signal produced at a threshold cycle within the purely exponential phase 20 of the PCR reaction reflects the starting copy number of the sequence of interest. Comparison of the starting copy number of the sequence of interest with the starting copy number of the internal control gene provides a relative gene expression level. TaqMan® analyses yield values that are expressed as ratios between two absolute measurements (gene of interest/internal control gene).



The PCR reaction mixture consisted 0.5 $\mu$ l of the reverse transcription reaction containing the cDNA prepared as described above 600 nM of each oligonucleotide primer (ERCC1-504F (SEQ ID NO:1),  $T_m$  = 59 $^\circ$  C and ERCC1-574R (SEQ ID NO: 2),  $T_m$  = 58 $^\circ$  C), 200 nM TaqMan $^\circ$  probe (SEQ ID NO:3), 5 U AmpliTaq Gold Polymerase, 200  $\mu$ M each dATP, dCTP, dGTP, 400  $\mu$ M dTTP, 5.5 mM MgCl<sub>2</sub>, and 1 x TaqMan $^\circ$  Buffer A containing a reference dye, to a final volume of less than or equal to 25  $\mu$ l (all reagents Applied Biosystems, Foster City, CA). Cycling conditions were, 95  $^\circ$ C for 10 min, followed by 45 cycles at 95  $^\circ$ C for 15s and 60  $^\circ$ C for 1 min. Oligonucleotides used to quantify internal control gene  $\beta$ -Actin were  $\beta$ -Actin TaqMan $^\circ$  probe (SEQ ID NO: 4),  $\beta$ -Actin-592F (SEQ ID NO: 5) and  $\beta$ -Actin-651R (SEQ ID NO: 6).

The oligonucleotide primers ERCC1-504F (SEQ ID NO:1) and ERCC1-574R (SEQ ID NO: 2), used in the above described reaction will amplify a 71bp product.

### 15      EXAMPLE 3

#### *Determining the Uncorrected Gene Expression (UGE) for ERCC1*

Two pairs of parallel reactions are carried out, i.e., "test" reactions and the "calibration" reactions. The *ERCC1* amplification reaction and the  $\beta$ -actin internal control amplification reaction are the test reactions. Separate *ERCC1* and  $\beta$ -actin amplification reactions are performed on the calibrator RNA template and are referred to as the calibration reactions. The TaqMan $^\circ$  instrument will yield four different cycle threshold (Ct) values: Ct<sub>ERCC1</sub> and Ct <sub>$\beta$ -actin</sub> from the test reactions and Ct<sub>ERCC1</sub> and Ct <sub>$\beta$ -actin</sub> from the calibration reactions. The differences in Ct values for

the two reactions are determined according to the following equation:

$$\begin{aligned}\Delta Ct_{\text{test}} &= Ct_{ERCC1} - Ct_{\beta\text{-actin}} && \text{(From the "test" reaction)} \\ \Delta Ct_{\text{calibrator}} &= Ct_{ERCC1} - Ct_{\beta\text{-actin}} && \text{(From the "calibration" reaction)}\end{aligned}$$

- 5        Next the step involves raising the number 2 to the negative  $\Delta Ct$ , according to the following equations.

$$\begin{aligned}2^{-\Delta Ct_{\text{test}}} &&& \text{(From the "test" reaction)} \\ 2^{-\Delta Ct_{\text{calibrator}}} &&& \text{(From the "calibration" reaction)}\end{aligned}$$

In order to then obtain an uncorrected gene expression for *ERCC1* from the

- 10    TaqMan® instrument the following calculation is carried out:

$$\text{Uncorrected gene expression (UGE) for } ERCC1 = 2^{-\Delta Ct_{\text{test}}} / 2^{-\Delta Ct_{\text{calibrator}}}$$

*Normalizing UGE with known relative ERCC1 expression levels*

- 15        The normalization calculation entails a multiplication of the UGE with a correction factor ( $K_{ERCC1}$ ) specific to *ERCC1* and a particular calibrator RNA. A correction factor  $K_{ERCC1}$  can also be determined for any internal control gene and any accurately pre-quantified calibrator RNA. Preferably, the internal control gene  $\beta$ -actin and the accurately pre-quantified calibrator RNA Human Liver Total RNA
- 20    (Stratagene, Cat. #735017), are used. Given these reagents correction factor  $K_{ERCC1}$  equals  $1.54 \times 10^{-3}$ .

- Normalization is accomplished using a modification of the  $\Delta Ct$  method described by Applied Biosystems, the TaqMan® manufacturer, in User Bulletin #2 and described above. To carry out this procedure, the UGE of 6 different test
- 25    tissues was analyzed for *ERCC1* expression using the TaqMan® methodology described above. The internal control gene  $\beta$ -actin and the calibrator RNA, Human

Liver Total RNA (Stratagene, Cat. #735017) was used.

The known relative *ERCC1* expression level of each sample AG221, AG222, AG252, Adult Lung, PC3, AdCol was divided by its corresponding TaqMan® derived UGE to yield an unaveraged correction factor K.

5 
$$K_{\text{unaveraged}} = \text{Known Values} / \text{UGE}$$

Next, all of the K values are averaged to determine a single  $K_{ERCC1}$  correction factor specific for *ERCC1*, Human Liver Total RNA (Stratagene, Cat. #735017) from calibrator RNA and  $\beta$ -actin.

10 Therefore, to determine the Corrected Relative *ERCC1* Expression in an unknown tissue sample on a scale that is consistent with pre-TaqMan® *ERCC1* expression studies, one merely multiplies the uncorrected gene expression data (UGE) derived from the TaqMan® apparatus with the  $K_{ERCC1}$  specific correction factor, given the use of the same internal control gene and calibrator RNA.

15 
$$\text{Corrected Relative } ERCC1 \text{ Expression} = \text{UGE} \times K_{ERCC1}$$

A  $K_{ERCC1}$  may be determined using any accurately pre-quantified calibrator RNA or internal control gene. Future sources of accurately pre-quantified RNA can be calibrated to samples with known relative *ERCC1* expression levels as described  
20 in the method above or may now be calibrated against a previously calibrated calibrator RNA such as Human Liver Total RNA (Stratagene, Cat. #735017) described above.

For example, if a subsequent  $K_{ERCC1}$  is determined for a different internal control gene and/or a different calibrator RNA, one must calibrate both the internal

control gene and the calibrator RNA to tissue samples for which *ERCC1* expression levels relative to that particular internal control gene have already been determined. Such a determination can be made using standard pre-TaqMan®, quantitative RT-PCR techniques well known in the art. The known expression levels for these

5 samples will be divided by their corresponding UGE levels to determine a K for that sample. K values are then averaged depending on the number of known samples to determine a new  $K_{ERCC1}$  specific to the different internal control gene and/or calibrator RNA.

10 EXAMPLE 4

All patients were enrolled in the Cisplatin/Gemcitabine arm of a prospective multicenter three arm randomized trial (GEPC/98-02, Spanish Lung Cancer Group Phase III trial of Cisplatin/Gemcitabine (CG) versus Cisplatin/ Gemcitabine / Vinorelbine (CGV) versus sequential doublets of Gemcitabine / Vinorelbine

15 followed by Ifosfamide / Vinorelbine (GV/IV) in advanced NSCLC). All patients received Gem 1250 mg/m<sup>2</sup> days 1,8 plus CDDP 100mg/m<sup>2</sup> day 1 every 3 weeks. Eligibility criteria for GEPC/98-02 were measurable stage IV (with brain metastases eligible if asymptomatic) or stage IIIB (malignant pleural and/or pericardial effusion and/or supraclavicular adenopathy) NSCLC and Eastern Cooperative Group (ECOG)

20 performance score 0-2. All patients had chest x-ray and a computed tomography (CT) scan of the chest and upper abdomen before entry into the study and underwent repeat evaluations at least every 6 weeks. Tumor response was assessed according to WHO criteria as complete response, partial response, stable disease, and progressive

disease. Tumors were reassessed during treatment with the same imaging methods used to establish the baseline tumor measurement.

Total mRNA was isolated from microdissected FPE pretreatment tumor samples, and Corrected Relative *ERCC1* Expression was measured using  
5 quantitative RT-PCR as described in Examples 2 and 3. A method for mRNA isolation from such samples is described in Example 1 and in US Patent Application No. 09/469,338, filed December 20, 1999, and is hereby incorporated by reference in its entirety.

#### *Statistical Analysis*

10 The Mann-Whitney U test was used to test for significant associations between the continuous test variable Corrected Relative *ERCC1* Expression and dichotomous variables (patient sex, age above and below the median age, presence of weight loss, presence of pleural effusion, tumor stage). The Kruskal-Wallis test was used to test for significant differences in Corrected Relative *ERCC1* Expression  
15 within multiple groups (ECOG performance status, histopathology). Fisher's exact test was used for the analysis of categorical clinicopathological values including response and dichotomized Corrected Relative *ERCC1* Expression values.

All patients were followed from first study treatment until death or until the data were censored. Kaplan-Meier survival curves and the log rank test were used to  
20 analyze univariate distributions for survival and disease-free survival. The maximal chi-square method of Miller and Siegmund (Biometrics 1982; 38:1011-1016 and Halpern (Biometrics 1982; 38:1017-1023) was adapted to determine which expression value best segregated patients into poor- and good prognosis subgroups

(in terms of likelihood of surviving), with the log-rank test as the statistic used to measure the strength of the grouping. To determine a P value that would be interpreted as a measure of the strength of the association based on the maximal chi-square analysis, 1000 boot-strap-like simulations were used to estimate the  
5 distribution of the maximal chi-square statistics under the hypothesis of no association. (Biometrics 1982; 38:1017-1023) Cox's proportional hazards modeling of factors that were significant in univariate analysis was performed to identify which factors might have a significant influence on survival. SPSS version 10.0.5 software (SPSS Inc., Chicago Ill.) was used for all statistical analyses. All P values were  
10 two-sided.

*Corrected Relative ERCC1 Expression Levels.*

*ERCC1* mRNA expression was detectable in all 56 samples analyzed. The median Corrected Relative *ERCC1* Expression, relative to the expression of the internal control housekeeping gene  $\beta$ -actin, was  $6.7 \times 10^{-3}$  (range  $0.8 \times 10^{-3} - 24.6 \times$   
15  $10^{-3}$ ). There were no significant associations between Corrected Relative *ERCC1* Expression levels and any of the factors age ( $P=0.66$ ), sex ( $P=0.18$ ) presence of weight loss in the six months prior to randomization ( $P=0.74$ ), tumor stage (IIIB versus IV,  $P=0.39$ ), or presence of pleural effusion ( $P=0.25$ , all Mann-Whitney U test). There were also no significant differences between the Corrected Relative  
20 *ERCC1* Expression levels among patients with different performance status grades ( $P=0.48$ , Kruskal-Wallis test) or different tumor cell types (all four tumor types,  $P=0.10$ , Kruskal-Wallis test), but Corrected Relative *ERCC1* Expression levels were

significantly higher in SCC tumors (median  $8.6 \times 10^{-3}$ ) compared to adenocarcinomas (median  $5.2 \times 10^{-3}$ ,  $P=0.015$ , Mann-Whitney test).

#### *Response to chemotherapy*

The tumor response frequencies for the 47 patients who were evaluable for response are shown in Figure 3. The overall response rate was 44.7%. The Corrected Relative *ERCC1* Expression levels in the complete response and partial response i.e. “responding” tumors (median  $4.3 \times 10^{-3}$ , range  $1.2 \times 10^{-3}$ - $24.6 \times 10^{-3}$ ) were not significantly different from the levels in the stable disease and progressive disease i.e. “non-responding” tumors (median  $7.85 \times 10^{-3}$ , range  $0.8 \times 10^{-3}$ - $24.3 \times 10^{-3}$ ,  $P=0.31$  Mann-Whitney test). There were also no significant differences between the proportion of responding and non-responding tumors with Corrected Relative *ERCC1* Expression values greater and less than any *ERCC1* level (all Fisher’s exact test). The response rate in tumors with Corrected Relative *ERCC1* Expression below the threshold value (“low” expression, 52% responders) was higher than for tumors with Corrected Relative *ERCC1* Expression above the threshold value (“high” expression, 36.4% responders, Fisher’s exact test,  $P = 0.38$ ).

#### *Association between patient overall survival and Corrected Relative ERCC1 Expression levels*

The median overall survival time was 36.6 weeks (range 0-113.4 weeks) and the median time to progression was 24.4 weeks (range 0-102.9 weeks). Use of the log rank test and the maximal chi-square statistic to identify threshold Corrected Relative *ERCC1* Expression levels that segregated patients into poor- and good-

prognosis subgroups showed that the range of discriminatory values included the median value, which was therefore used as the threshold value for the survival analysis. Therefore, the threshold Corrected Relative *ERCC1* Expression value was determined to be  $6.7 \times 10^{-3}$  for NSCLC. Figure 1 shows the Kaplan-Meier survival curve for patients with intratumoral Corrected Relative *ERCC1* Expression levels above and below the threshold Corrected Relative *ERCC1* Expression level. As shown in Figure 4, patients with Corrected Relative *ERCC1* Expression levels below the threshold value had a significantly longer median survival of 61.6 weeks (95% C.I. 42.4, 80.7 weeks) compared to 20.4 weeks (95% C.I. 6.9, 33.9 weeks) for patients with Corrected Relative *ERCC1* Expression levels above the threshold value. Adjusted for tumor stage, the log rank statistic for the association between low or high Corrected Relative *ERCC1* Expression and overall survival was 3.97 and the P value was 0.046. The unadjusted log rank results are shown in Figure 4.

A separate Corrected Relative *ERCC1* Expression threshold value of  $5.8 \times 10^{-3}$  was tested because this value was shown in a previous study to be associated with overall survival for patients with gastric cancer. (Metzger et al., J Clin Oncol 1998; 16:309-316). Overall survival was significantly better for the group of NSCLC patients in this study with Corrected Relative *ERCC1* Expression levels less than  $5.8 \times 10^{-3}$  compared to those with *ERCC1* levels less than  $5.8 \times 10^{-3}$  (log rank statistic 6.37, P=0.011), although a higher  $6.7 \times 10^{-3}$  Corrected Relative *ERCC1* Expression threshold level is a more powerful discriminator.

Other factors that were significantly associated with overall survival on univariable analysis using Kaplan Meier survival curves and the log rank test were the presence of pretreatment weight loss and the ECOG performance status (Table



2). Patient age ( $P=0.18$ ), sex ( $P=0.87$ ), tumor stage ( $P=0.99$ ), tumor cell type ( $P=0.63$ ), and presence of pleural effusion ( $P=0.71$ ) were not significant prognostic factors for overall survival. Corrected Relative *ERCC1* Expression level, ECOG performance status, and weight loss remained significant prognostic factors for survival in the Cox proportional hazards regression model multivariable analysis (Figure 4). P values for a Cox regression model stratified on tumor stage were 0.038 for *ERCC1*, 0.017 for weight loss, and 0.02 for ECOG performance status (PS 0 versus 1 or 2).

This study found an association between lower *ERCC1* mRNA expression levels and improved survival after treatment with a platinum-based chemotherapeutic for patients with cancer.

## CLAIMS

1. A method for determining a platinum-based chemotherapeutic regimen for treating a tumor in a patient comprising:
  - (a) obtaining a tissue sample of the tumor and fixing the sample, to  
5 obtain a fixed tumor sample;
  - (b) isolating mRNA from the fixed tumor sample;
  - (c) subjecting the mRNA to amplification using a pair of oligonucleotide primers that hybridize under stringent conditions to a region of the *ERCC1* gene, to obtain an amplified sample;
  - 10 (d) determining the amount of *ERCC1* mRNA in the amplified sample;
  - (e) comparing the amount of *ERCC1* mRNA from step (d) to an amount of mRNA of an internal control gene; and
  - (f) determining a platinum-based chemotherapeutic regimen based on the amount of *ERCC1* mRNA in the amplified sample and a  
15 predetermined threshold level for *ERCC1* gene expression.
2. The method of claim 1 wherein the oligonucleotide primers consist of the oligonucleotide primer pair ERCC1, or pair of oligonucleotide primers substantially identical thereto.
3. The method of claim 1 wherein, the tumor is a non-small-cell lung cancer  
20 (NSCLC) tumor.

4. The method of claim 1 wherein, the threshold level of *ERCC1* gene expression is about  $6.7 \times 10^{-3}$  times internal control gene expression level.
5. A method of treating a tumor with a platinum-based chemotherapeutic regimen comprising:
- 5 (a) obtaining a tissue sample of the tumor and fixing the sample, to obtain a fixed tumor sample;
- (b) isolating mRNA from the fixed tumor sample;
- (c) subjecting the mRNA to amplification using a pair of oligonucleotide primers that hybridize under stringent
- 10 conditions to a region of the *ERCC1* gene, to obtain an amplified sample;
- (d) determining the amount of *ERCC1* mRNA in the amplified sample;
- (e) comparing the amount of *ERCC1* mRNA from step (d) to an
- 15 amount of mRNA of an internal control gene;
- (f) providing a platinum-based chemotherapeutic regimen comprising a genotoxic agent when the determined gene expression level for *ERCC1* gene is below a predetermined threshold value.
- 20 6. The method of claim 5 wherein, the tumor is a non-small-cell lung cancer (NSCLC) tumor.

7. The method of claim 5 wherein, the genotoxic agent is gemcitabine, cisplatin or a combination thereof.
8. A method for determining the level of *ERCC1* expression in a fixed paraffin emedded tissue sample comprising;
  - 5 (a) deparaffinizing the tissue sample; to obtain a deparaffinized sample;
  - (b) isolating mRNA from the deparaffinized sample in the presence of an effective amount of a chaotropic agent;
  - (c) subjecting the mRNA to amplification using a pair of oligonucleotide primers that hybridize under stringent conditions to a region of the  
10 *ERCC1* gene, to obtain an amplified sample;
  - (d) determining the quantity of *ERCC1* mRNA relative to the quantity of an internal control gene's mRNA.
9. The method of claim 8 wherein, the pair of oligonucleotide primers consists of the oligonucleotide primer pair ERCC1 or a pair of oligonucleotide  
15 primers substantially similar thereto.
10. The method of claim 8 wherein, the internal control gene is  $\beta$ -actin.
11. The method of claim 8 wherein, mRNA isolation is carried out by
  - (a) heating the tissue sample in a solution comprising an effective concentration of a chaotropic compound to a temperature in the range

of about 75 to about 100 °C for a time period of about 5 to about 120 minutes;

and

(b) recovering said mRNA from said chaotropic solution.

5

12. An oligonucleotide primer having the sequence of SEQ ID NO: 1 or and an oligonucleotide substantially identical thereto.

13. An oligonucleotide primer having the sequence of SEQ ID NO: 2 or and an oligonucleotide substantially identical thereto.

10 14. A kit for detecting expression of an *ERCC1* gene comprising, oligonucleotide pair *ERCC1* or an oligonucleotide pair substantially identical thereto.

Figure 1




Figure 2: Chart illustrating how to calculate *ERCC1* expression relative to an internal control gene

	From test reactions				From calibration reactions				Unknown ERCC1 expression (log <sub>2</sub> )				Known ERCC1 (log <sub>2</sub> )		Normalized (log <sub>2</sub> )		Relative ERCC1 (log <sub>2</sub> )	
	Sample	C <sub>t</sub> ERCC1	C <sub>t</sub> β-actin	ΔC <sub>t</sub>	2 <sup>-ΔC<sub>t</sub></sup>	C <sub>t</sub> Calib. RNA	C <sub>t</sub> β-actin	ΔC <sub>t</sub>	2 <sup>-ΔC<sub>t</sub></sup>	2 <sup>-ΔC<sub>t</sub></sup>	2 <sup>-ΔC<sub>t</sub></sup>	2 <sup>-ΔC<sub>t</sub></sup>	Known ERCC1 (log <sub>2</sub> )	Known ERCC1 (log <sub>2</sub> )	Normalized (log <sub>2</sub> )	Normalized (log <sub>2</sub> )	Relative ERCC1 (log <sub>2</sub> )	Relative ERCC1 (log <sub>2</sub> )
Experimental	unknown 1	26.68	21.17	7.51	0.00549	-	-	-	-	-	0.737	-	-	-	-	1.54 x 10 <sup>-3</sup>	1.13 x 10 <sup>-3</sup>	-
	unknown 2	24.8	17.64	7.16	0.00699	-	-	-	-	-	0.9395	-	-	-	-	1.54 x 10 <sup>-3</sup>	1.45 x 10 <sup>-3</sup>	-
	Calib. RNA	-	-	-	-	27.81	20.71	7.07	0.0074	0.0074	0.0074/0.0074 = 1	-	-	-	-	-	-	-
From Known samples	AG221	34.46	28.56	5.9	0.167	-	-	-	-	-	2.81	-	4.32 x 10 <sup>-3</sup>	1.54 x 10 <sup>-3</sup>	1.54 x 10 <sup>-3</sup>	1.54 x 10 <sup>-3</sup>	-	-
	AG222	33.93	27.21	6.72	0.0095	-	-	-	-	-	1.59	-	2.45 x 10 <sup>-3</sup>	1.54 x 10 <sup>-3</sup>	1.54 x 10 <sup>-3</sup>	1.54 x 10 <sup>-3</sup>	-	-
	AG252	36.9	29.43	7.47	0.0056	-	-	-	-	-	0.946	-	1.46 x 10 <sup>-3</sup>	1.54 x 10 <sup>-3</sup>	1.54 x 10 <sup>-3</sup>	1.54 x 10 <sup>-3</sup>	-	-
	Adult lung	25.2	17.3	8	0.0039	-	-	-	-	-	0.655	-	1.009 x 10 <sup>-3</sup>	1.54 x 10 <sup>-3</sup>	1.54 x 10 <sup>-3</sup>	1.54 x 10 <sup>-3</sup>	-	-
	PC3	24.51	16.47	8.04	0.0038	-	-	-	-	-	0.637	-	0.981 x 10 <sup>-3</sup>	1.54 x 10 <sup>-3</sup>	1.54 x 10 <sup>-3</sup>	1.54 x 10 <sup>-3</sup>	-	-
	AdCal	24.48	16.75	7.71	0.0048	-	-	-	-	-	0.801	-	1.233 x 10 <sup>-3</sup>	1.54 x 10 <sup>-3</sup>	1.54 x 10 <sup>-3</sup>	1.54 x 10 <sup>-3</sup>	-	-
	Calib. RNA	-	-	-	-	25.86	18.57	7.39	0.00596	0.00596	0.00596/0.00596 = 1	-	-	-	-	-	-	-

Figure 3. Patient Characteristics

	N (%)
No. of patients	56 (100)
Sex	
Male	48 (85.7)
Female	8 (14.3)
Age, years	
Median	60.5
Range	32-75
ECOG performance status	
0	13 (23.2)
1	35 (62.5)
2	8 (14.3)
Weight loss	21 (37.5)
Stage	
IIIB	16 (28.6)
IV	40 (71.4)
Pleural effusion	11 (19.6)
Histopathology	
Adenocarcinoma	30 (53.6)
Squamous	20 (35.7)
Large cell	4 (7.1)
Undifferentiated	2 (3.6)
Response	
Complete response	3 (5.4)
Partial response	18 (32.1)
Stable disease	8 (14.3)
Progressive disease	18 (32.1)
Not evaluable	9 (16.1)



Figure 4. Factors associated with overall survival

	Median Survival (weeks)	Univariable Analysis		Multivariable Analysis	
		Log rank statistic	P value	Hazard ratio (95% C.I.)	P value
ERCC1 expression					
Low*	62	6.78	0.009	0.32 (0.14-0.71)	0.005
High*	20				
Weight loss					
Absent	46	8.89	<0.003	0.36 (0.17-0.75)	0.007
Present	14				
ECOG performance status					
0	61 31 5	10.29	<0.005	(0 versus 1 or 2) 0.26 (0.09-0.76)	0.014
1					
2					

\*Corrected Relative *ERCC1* expression values categorized according to whether less than the Corrected Relative *ERCC1* threshold value of  $6.7 \times 10^{-3}$  ("low expression") or greater than the threshold ("high expression").

## SEQUENCE LISTING

<110> Danenberg, Kathleen

<120> METHOD OF DETERMINING A CHEMOTHERAPEUTIC  
REGIMEN BASED ON ERCC1 EXPRESSION

<130> 11220/145

<140> Not assigned

<141> - -

<150> 09/877,095

<151> 2001-06-11

<150> 09/796,491

<151> 2001-03-02

<160> 7

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide Primer

<400> 1

gggaatttgg cgacgtaatt c

21

<210> 2

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide Primer

<400> 2

gcggaggetg aggaacag

18

<210> 3

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide Primer

<400> 3

cacaggtgct ctggcccagc acata

25

<210> 4

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

## &lt;223&gt; Oligonucleotide Primer

&lt;400&gt; 4

accaccacgg ccgagcgg

18

&lt;210&gt; 5

&lt;211&gt; 18

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Oligonucleotide Primer

&lt;400&gt; 5

tgagcgcggc tacagctt

18

&lt;210&gt; 6

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Oligonucleotide Primer

&lt;400&gt; 6

tccttaattgt caccgacgat

20

&lt;210&gt; 7

&lt;211&gt; 1097

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 7

```

aagtgtgctg agccctgggc cagcgtggcc gtgctggcag tgggcccgcct cgatccctct 60
gcagtctttc ccttgaggct ccaagaccag caggtgaggc ctgcgcggcg tgaaaccgtg 120
aggcccggac cacaggctcc agatggaccc tgggaaggac aaagaggggg tgccccagcc 180
ctcagggccg ccagcaagga agaaatttgt gataccctc gacgaggatg aggtccctcc 240
tggagtggcc aagcccttat tccgatctac acagagcctt cccactgtgg acacctcggc 300
ccaggcggcc cctcagacct acgccgaata tgccatctca cagcctctgg aaggggctgg 360
ggccacgtgc cccacagggt cagagcccct ggcaggagag acgcccacc aggccctgga 420
accgggggca aaatccaaca gcatcattgt gagccctcgg cagaggggca atcccgtact 480
gaagttcgtg cgcaacgtgc cctgggaatt tggcgacgta attcccgact atgtgcccgg 540
ccagagcacc tgtgccctgt tectcagcct ccgctaccac aacctgcacc cagactacat 600
ccatgggcgg ctgcagagcc tggggaagaa ctctgccttg cgggtcctgc ttgtccaggt 660
ggatgtgaaa gatccccagc aggccctcaa ggagctggct aagatgtgta tcctggccga 720
ctgcacattg atcctgcct ggagccccga ggaagctggg cggtaacctg agacctataa 780
ggcctatgag cagaaaccag cggacctcct gatggagaag ctagagcagg acttcgtctc 840
ccgggtgact gaatgtctga ccaccgtgaa gtcagtcaac aaacaggaca gtcagacct 900
cctgaccaca tttggatctc tggaaacagc catcgcggca tcaagagaag atctggcctt 960
atgccaggc ctgggccctc agaaagcccg agggctgttt gatgtcctgc acgagccctt 1020
cttgaaagta ccctgatgac cccagctgac aaggaaacct ccagtgtaat aataaatcgt 1080
cctcccaggc caggctc

```

1097

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
8 August 2002 (08.08.2002)

PCT

(10) International Publication Number  
**WO 02/061128 A3**

(51) International Patent Classification<sup>7</sup>: **C12Q 1/68**,  
G01N 33/574, 33/50

(74) Agents: **MELORO, Thomas et al.**; Kenyon & Kenyon,  
1500 K Street, N.W., Suite 700, Washington, DC 20005  
(US).

(21) International Application Number: PCT/US01/44519

(22) International Filing Date:  
29 November 2001 (29.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/250,121 1 December 2000 (01.12.2000) US  
60/250,470 4 December 2000 (04.12.2000) US  
09/796,491 2 March 2001 (02.03.2001) US  
09/877,095 11 June 2001 (11.06.2001) US  
09/988,784 20 November 2001 (20.11.2001) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,  
ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH; GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).


(71) Applicant: **RESPONSE GENETICS, INC.** [US/US];  
1640 Marengo Street, 6th Floor, Los Angeles, CA 90033  
(US).

(72) Inventor: **DANENBERG, Kathleen, D.**; 3367 Rubio  
Crest Drive, Altadena, CA 91001 (US).

**Published:**  
— with international search report

[Continued on next page]

(54) Title: METHOD OF DETERMINING A CHEMOTHERAPEUTIC REGIMEN BASED ON *ERCC1* EXPRESSION



(57) Abstract: The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing *ERCC1* expression levels in fixed or fixed and paraffin embedded tissues and determine a platinum-based chemotherapy by examination of the amount of *ERCC1* mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level. More specifically, the invention provides to oligonucleotide primer pair *ERCC1* and methods comprising their use for detecting levels of *ERCC1* mRNA.

WO 02/061128 A3

**WO 02/061128 A3**



**(88) Date of publication of the international search report:**  
25 September 2003

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

# INTERNATIONAL SEARCH REPORT

International application No

PCT/US 01/44519

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68 G01N33/574 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, EMBASE, CHEM ABS Data, WPI Data, PAJ, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 705 336 A (DABHOLKAR MEENAKSHI ET AL) 6 January 1998 (1998-01-06) cited in the application	14
Y	column 5, line 59 -column 6, line 5 abstract	1,2,4,5, 7-10
A	column 3, line 36 -column 4, line 39; examples 1,2	3,6, 11-13
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

16 January 2003

Date of mailing of the international search report

31/01/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Tilkorn, A-C

## INTERNATIONAL SEARCH REPORT

Internationa Application No

PCT/US 01/44519

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	METZGER RALF ET AL: "ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy." JOURNAL OF CLINICAL ONCOLOGY, vol. 16, no. 1, January 1998 (1998-01), pages 309-316, XP002226040 ISSN: 0732-183X page 310, column 2, paragraph 3	14
Y	abstract	1,2,4,5, 7-10
A	page 312, column 2, paragraph 2 - paragraph 3; figure 1 page 314, column 1, paragraph 1 -page 315, column 2, paragraph 1	3,6, 11-13
Y	--- GODFREY T E ET AL: "Quantitative mRNA expression analysis from formalin-fixed, paraffin-embedded tissues using 5' nuclease quantitative reverse transcription-polymerase chain reaction." THE JOURNAL OF MOLECULAR DIAGNOSTICS: JMD. UNITED STATES MAY 2000, vol. 2, no. 2, May 2000 (2000-05), pages 84-91, XP002226042 ISSN: 1525-1578 the whole document	1,2,4,5, 7-10
Y	--- KOOPMANS M ET AL: "OPTIMIZATION OF EXTRACTION AND PCR AMPLIFICATION OF RNA EXTRACTS FROM PARAFFIN-EMBEDDED TISSUE IN DIFFERENT FIXATIVES" JOURNAL OF VIROLOGICAL METHODS, AMSTERDAM, NL, vol. 43, no. 2, 1993, pages 189-204, XP000997425 ISSN: 0166-0934 abstract page 193, paragraph 2 -page 194, paragraph 2; figure 1 page 197, paragraph 1 -page 200, paragraph 2 --- -/--	1,2,4,5, 7-10

## INTERNATIONAL SEARCH REPORT

Internation application No  
PCT/US 01/44519

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
A	<p>TSAI C-M ET AL: "INTERRELATIONSHIPS BETWEEN CELLULAR NUCLEOTIDE EXCISION REPAIR, CISPLATIN CYTOTOXICITY, HER-2/NEU GENE EXPRESSION, AND EPIDERMAL GROWTH FACTOR RECEPTOR LEVEL IN NON-SMALL CELL LUNG CANCER CELLS"</p> <p>JAPANESE JOURNAL OF CANCER RESEARCH, JAPANESE CANCER ASSOCIATION, TOKYO, JP, vol. 91, no. 2, February 2000 (2000-02), pages 213-222, XP009002501</p> <p>ISSN: 0910-5050</p> <p>abstract</p> <p>figure 1</p>	1-14
A	<p>BRITTEN RICHARD A ET AL: "ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells."</p> <p>INTERNATIONAL JOURNAL OF CANCER, vol. 89, no. 5, 2000, pages 453-457, XP002226041</p> <p>ISSN: 0020-7136</p> <p>the whole document</p>	1-14
A	<p>DUIN VAN M ET AL: "MOLECULAR CHARACTERIZATION OF THE HUMAN EXCISION REPAIR GENE ERCC-1: CDNA CLONING AND AMINO ACID HOMOLOGY WITH THE YEAST DNA REPAIR GENE RAD10"</p> <p>CELL, MIT PRESS, CAMBRIDGE, MA., US, vol. 44, no. 6, 28 March 1986 (1986-03-28), pages 913-923, XP009002541</p> <p>ISSN: 0092-8674</p> <p>the whole document</p>	12,13
P,X	<p>SHIROTA YOSHINORI ET AL: "ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy."</p> <p>JOURNAL OF CLINICAL ONCOLOGY, vol. 19, no. 23, 1 December 2001 (2001-12-01), pages 4298-4304, XP009002481</p> <p>December 1, 2001</p> <p>ISSN: 0732-183X</p> <p>table 1</p>	12-14
P,Y	<p>US 6 248 535 B1 (DANENBERG PETER V ET AL)</p> <p>19 June 2001 (2001-06-19)</p> <p>cited in the application</p> <p>the whole document</p>	1-11
-/--		



# INTERNATIONAL SEARCH REPORT

Internat. Application No.  
PCT/US 01/44519

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, Y	MONZO M ET AL: "DRUG RESISTANCE IN NON-SMALL CELL LUNG CANCER" LUNG CANCER, ELSEVIER, AMSTERDAM, NL, vol. 34, no. SUPPL 2, 2001, pages S91-S94, XP001118946 ISSN: 0169-5002 the whole document	1-11
E	WO 02 057489 A (RESPONSE GENETICS INC) 25 July 2002 (2002-07-25) the whole document	1-14

## INTERNATIONAL SEARCH REPORT

Int'l application No.  
PCT/US 01/44519

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-7  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: 2,9,14 (partially)  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box I.1

Claims 1-7 comprise a surgical step, namely step (a) which falls under Rule 39.1 (iv) PCT.  
Moreover, claims 5-7 pertain to a method of treatment and are also for this reason covered by Rule 39.1(iv) PCT.  
Thus, claims 1-7 have been searched on the basis of the alleged effects.

-----

Continuation of Box I.1

Claims Nos.: 1-7

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

-----

Continuation of Box I.2

Claims Nos.: 2,9,14 (partially)

The feature "oligonucleotide pair ERCC1" is merely an arbitrary designation, the technical nature of which is undefined (Art 6 PCT). From the application it is understood that by the term "oligonucleotide pair ERCC1" the oligonucleotide pair defined by SEQ ID NOs 1 and 2 is meant. Therefore, claims 2,9 and 14 have been searched only with respect to the primer pair defined by SEQ ID NOs 1 and 2.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US 01/44519

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5705336	A	06-01-1998	NONE	
US 6248535	B1	19-06-2001	AU 1578501 A	03-07-2001
			EP 1242594 A1	25-09-2002
			NO 20022945 A	06-08-2002
			WO 0146402 A1	28-06-2001
			US 2002009794 A1	24-01-2002
			US 2002009795 A1	24-01-2002
			US 2001029018 A1	11-10-2001
WO 02057489	A	25-07-2002	WO 02057489 A2	25-07-2002
			AU 2001202 A	11-06-2002
			WO 0244423 A2	06-06-2002